Shandong Weigao Blood Purification Products Co., Ltd. (SHA:603014)
China · Delayed Price · Currency is CNY 29.48
+0.42 (1.45%)
At close: Oct 23, 2026
SHA:603014 Revenue
Shandong Weigao Blood Purification Products had revenue of 853.98M CNY in the quarter ending June 30, 2026, a decrease of -1.69%. This brings the company's total for the last twelve months to 3.76B, up 0.52% year-over-year. In the year 2025, Shandong Weigao Blood Purification Products had annual revenue of 3.77B with 4.57% growth. That makes Shandong Weigao Blood Purification Products the 10,561st largest company in the world by revenue and 1,733rd in China.
Revenue (ttm)
3.76B
Revenue Growth
+0.52%
P/S Ratio
3.27
Revenue / Employee
n/a
Employees
3,734
Market Cap
12.32B
Revenue by Geography
- Mainland China 3.44B 91.3%
- Other Countries and Regions 329.26M 8.7%
Fiscal year ended Dec 31, 2025 See the full SHA:603014 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.77B | 164.70M | 4.57% |
| Dec 31, 2024 | 3.60B | 71.87M | 2.03% |
| Dec 31, 2023 | 3.53B | 106.03M | 3.09% |
| Dec 31, 2022 | 3.43B | 515.59M | 17.71% |
| Dec 31, 2021 | 2.91B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sinocare | 4.93B |
| Cofoe Medical Technology | 3.96B |
| Double Medical Technology | 2.73B |
| Qingdao Haier Biomedical Co.,Ltd | 2.43B |
| Jafron Biomedical | 1.91B |
| MeHow Innovative | 1.71B |
| Shandong Weigao Orthopaedic Device | 1.49B |
| Shanghai MicroPort Endovascular MedTech | 1.43B |